Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 11:2022:6619331.
doi: 10.1155/2022/6619331. eCollection 2022.

Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism

Fangfang Hao  1   2 , Jinliang Chen  2 , Jinnan Wu  3 , Xin Ge  4 , Xuedong Lv  2 , Dongmei Zhang  4 , Jianrong Chen  2   4
Affiliations

Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism

Fangfang Hao et al. Can Respir J. .

Abstract

Objective: The aim of this study was to investigate the expression level of soluble LOX-1 (sLOX-1) in the serum of non-small-cell lung cancer (NSCLC) patients and its correlation with lipid metabolism.

Methods: 99 inpatients with NSCLC and 81 healthy controls were enrolled in this study. The levels of serum sLOX-1 were compared between the two groups, and the correlation of sLOX-1 with clinicopathological characteristics, blood lipid indices, and carcinoembryonic antigen was analyzed.

Results: Compared with the healthy controls, sLOX-1, low-density lipoprotein, triglyceride, and carcinoembryonic antigen in the patients with NSCLC were significantly higher (p < 0.05), while the expression level of high-density lipoprotein was lower (p < 0.05). The expression level of sLOX-1 in the serum of patients with healthy controls was positively correlated with low-density lipoprotein (r = 0.72, p < 0.05). The levels of sLOX-1 and low-density lipoprotein in the serum of patients with NSCLC were closely related to the lymph node metastasis, distant metastasis, and TNM stage (p < 0.05). Compared with a single index, when the sLOX-1 was combined with the CEA, its specificity increased significantly to 97.5% (AUC = 0.995, p < 0.01, 95% CI: 0.989-1.000).

Conclusion: sLOX-1 and low-density lipoprotein were overexpressed in the serum of patients with NSCLC, positively correlated, and closely related to the TNM stage and metastasis. This result suggested that lipid metabolic disorders may promote the progression of NSCLC through sLOX-1, which could be a potential serological marker with diagnostic value for NSCLC.

PubMed Disclaimer

Conflict of interest statement

The author (s) declare no conflicts of interest.

Figures

Figure 1
Figure 1
Expression levels of sLOX-1, LDL, HDL, and TG in serum of patients with NSCLC stage I–II and stage III–IV. ns: no significance.∗∗p < 0.01. ∗∗∗p < 0.001.
Figure 2
Figure 2
Correlation of serum sLOX-1 with blood lipid LDL.
Figure 3
Figure 3
The diagnostic value of sLOX-1 and CEA single index and combination for NSCLC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians . 2019;69(1):7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Barta J. A., Powell C. A., Wisnivesky J. P. Global epidemiology of lung cancer[J] Ann Glob Health . 2019;85(1):p. 8. doi: 10.5334/aogh.2419. - DOI - PMC - PubMed
    1. Nasim F., Sabath B. F., Eapen G. A. Lung cancer. Medical Clinics of North America . 2019;103(3):463–473. doi: 10.1016/j.mcna.2018.12.006. - DOI - PubMed
    1. Wang X., Liu H., Shen Y., Li W., Chen Y., Wang H. Low-dose computed tomography (LDCT) versus other cancer screenings in early diagnosis of lung cancer. Medicine . 2018;97(27) doi: 10.1097/md.0000000000011233.e11233 - DOI - PMC - PubMed
    1. Beloribi-Djefaflia S., Vasseur S., Guillaumond F., et al. Lipid metabolic reprogramming in cancer cells. Oncogenesis . 2016;5(1):p. e189. doi: 10.1038/oncsis.2015.49. - DOI - PMC - PubMed

MeSH terms